329 related articles for article (PubMed ID: 33115942)
1. Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response.
Qi X; Yang M; Ma L; Sauer M; Avella D; Kaifi JT; Bryan J; Cheng K; Staveley-O'Carroll KF; Kimchi ET; Li G
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33115942
[TBL] [Abstract][Full Text] [Related]
2. The Efficacy and Therapeutic Outcome of Bipolar Radiofrequency Ablation for the Treatment for Hepatocellular Carcinoma in the Real-World Setting, Compared with Monopolar Radiofrequency Ablation Conducted during the Same Period.
Tanaka T; Takata K; Kunimoto H; Fukuda H; Yamauchi R; Tsuchiya N; Inomata S; Yokoyama K; Morihara D; Takeyama Y; Shakado S; Sakisaka S; Hirai F
Oncology; 2020; 98(12):859-868. PubMed ID: 32799203
[TBL] [Abstract][Full Text] [Related]
3. STING agonist-based hydrogel enhances immune activation in synergy with radiofrequency ablation for hepatocellular carcinoma treatment.
Ao F; Li X; Tan Y; Jiang Z; Yang F; Guo J; Zhu Q; Chen Z; Zhou B; Zhang K; Li D
J Control Release; 2024 May; 369():296-308. PubMed ID: 38301925
[TBL] [Abstract][Full Text] [Related]
4. PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor.
Shi L; Chen L; Wu C; Zhu Y; Xu B; Zheng X; Sun M; Wen W; Dai X; Yang M; Lv Q; Lu B; Jiang J
Clin Cancer Res; 2016 Mar; 22(5):1173-1184. PubMed ID: 26933175
[TBL] [Abstract][Full Text] [Related]
5. Enhanced efficacy of radiofrequency ablation for hepatocellular carcinoma using a novel vascular disrupting agent, CKD-516.
Ham SJ; Choi Y; Lee SI; Kim J; Kim YI; Chung JW; Kim KW
Hepatol Int; 2017 Sep; 11(5):446-451. PubMed ID: 28721452
[TBL] [Abstract][Full Text] [Related]
6. TLR9 agonist enhances radiofrequency ablation-induced CTL responses, leading to the potent inhibition of primary tumor growth and lung metastasis.
Xu A; Zhang L; Yuan J; Babikr F; Freywald A; Chibbar R; Moser M; Zhang W; Zhang B; Fu Z; Xiang J
Cell Mol Immunol; 2019 Oct; 16(10):820-832. PubMed ID: 30467420
[TBL] [Abstract][Full Text] [Related]
7. Development of a radiofrequency ablation platform in a clinically relevant murine model of hepatocellular cancer.
Qi X; Li G; Liu D; Motamarry A; Huang X; Wolfe AM; Helke KL; Haemmerich D; Staveley-O'Carroll KF; Kimchi ET
Cancer Biol Ther; 2015; 16(12):1812-9. PubMed ID: 26537481
[TBL] [Abstract][Full Text] [Related]
8. Integrated proteogenomic characterization reveals an imbalanced hepatocellular carcinoma microenvironment after incomplete radiofrequency ablation.
Shi ZR; Duan YX; Cui F; Wu ZJ; Li MP; Song PP; Peng QL; Ye WT; Yin KL; Kang MQ; Yu YX; Yang J; Tang W; Liao R
J Exp Clin Cancer Res; 2023 May; 42(1):133. PubMed ID: 37231509
[TBL] [Abstract][Full Text] [Related]
9. Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model.
Avella DM; Li G; Schell TD; Liu D; Zhang SS; Lou X; Berg A; Kimchi ET; Tagaram HR; Yang Q; Shereef S; Garcia LS; Kester M; Isom HC; Rountree CB; Staveley-O'Carroll KF
Hepatology; 2012 Jan; 55(1):141-52. PubMed ID: 21898502
[TBL] [Abstract][Full Text] [Related]
10. Insufficient radiofrequency ablation promotes the metastasis of residual hepatocellular carcinoma cells via upregulating flotillin proteins.
Zhang N; Li H; Qin C; Ma D; Zhao Y; Zhu W; Wang L
J Cancer Res Clin Oncol; 2019 Apr; 145(4):895-907. PubMed ID: 30820716
[TBL] [Abstract][Full Text] [Related]
11. Irreversible electroporation induces CD8
Dai Z; Wang Z; Lei K; Liao J; Peng Z; Lin M; Liang P; Yu J; Peng S; Chen S; Kuang M
Cancer Lett; 2021 Apr; 503():1-10. PubMed ID: 33444692
[TBL] [Abstract][Full Text] [Related]
12. Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.
Li G; Liu D; Cooper TK; Kimchi ET; Qi X; Avella DM; Li N; Yang QX; Kester M; Rountree CB; Kaifi JT; Cole DJ; Rockey DC; Schell TD; Staveley-O'Carroll KF
J Hepatol; 2017 Jan; 66(1):75-85. PubMed ID: 27520877
[TBL] [Abstract][Full Text] [Related]
13. Radiofrequency ablation plays double role in immunosuppression and activation of PBMCs in recurrent hepatocellular carcinoma.
Zhao Y; Yang T; Ouyang Y; Rao W; Liu K; Zheng J; Lv F; Shi Y; Wang F; Liu D; Qiao L; Xia Z; Zhang Y; Chen D; Wang W
Front Immunol; 2024; 15():1339213. PubMed ID: 38348038
[TBL] [Abstract][Full Text] [Related]
14. RFA strongly modulates the immune system and anti-tumor immune responses in metastatic liver patients.
Napoletano C; Taurino F; Biffoni M; De Majo A; Coscarella G; Bellati F; Rahimi H; Pauselli S; Pellicciotta I; Burchell JM; Gaspari LA; Ercoli L; Rossi P; Rughetti A
Int J Oncol; 2008 Feb; 32(2):481-90. PubMed ID: 18202772
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effect of OK-432 in combination with an anti-PD-1 antibody for residual tumors after radiofrequency ablation of hepatocellular carcinoma.
Sun T; Sun B; Cao Y; Liu J; Chen J; Liang B; Zheng C; Kan X
Biomed Pharmacother; 2023 Oct; 166():115351. PubMed ID: 37625323
[TBL] [Abstract][Full Text] [Related]
16. Combination of Radiofrequency Ablation With Resiquimod to Treat Hepatocellular Carcinoma
Tian Z; Hong B; Chen J; Tang Z
Front Oncol; 2022; 12():891724. PubMed ID: 35719978
[TBL] [Abstract][Full Text] [Related]
17. MTL-CEBPA Combined with Immunotherapy or RFA Enhances Immunological Anti-Tumor Response in Preclinical Models.
Huang KW; Tan CP; Reebye V; Chee CE; Zacharoulis D; Habib R; Blakey DC; Rossi JJ; Habib N; Sodergren MH
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502076
[TBL] [Abstract][Full Text] [Related]
18. Correlation Between Contrast-Enhanced Ultrasound and Immune Response of Distant Hepatocellular Carcinoma After Radiofrequency Ablation in a Murine Model.
Wang P; Tian M; Ren W
J Ultrasound Med; 2022 Mar; 41(3):713-723. PubMed ID: 34018628
[TBL] [Abstract][Full Text] [Related]
19. Incomplete radiofrequency ablation induced chemoresistance by up-regulating heat shock protein 70 in hepatocellular carcinoma.
Wang F; Xu C; Li G; Lv P; Gu J
Exp Cell Res; 2021 Dec; 409(2):112910. PubMed ID: 34801560
[TBL] [Abstract][Full Text] [Related]
20. Targeting autophagy enhances heat stress-induced apoptosis via the ATP-AMPK-mTOR axis for hepatocellular carcinoma.
Jiang J; Chen S; Li K; Zhang C; Tan Y; Deng Q; Chai Y; Wang X; Chen G; Feng K; Zhang L; Xie CM; Ma K
Int J Hyperthermia; 2019; 36(1):499-510. PubMed ID: 31007109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
